Immunotoxicity profile of natalizumab

Journal of Immunotoxicology

Volumn 6, Issue 2, 2009, Pages 115-129

  Wehner, Nancy G ^a   Gasper, Carolyn ^b   Shopp, George ^c   Nelson, Joyce ^d   Draper, Ken ^d   Parker, Suezanne ^e   Clarke, Janet ^e  

^a ELAN PHARMACEUTICALS   (United States)

^b XOMA Corporation   (United States)

^c Shopp Nonclinical Consulting LLC   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e BIOGEN   (United States)

Author keywords

4 integrin; Immune function; Macaca fascicularis; Macaca mulatta; Monoclonal antibody; NatAlizumab

Indexed keywords

NATALIZUMAB; ALPHA4 INTEGRIN; CYTOKINE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; EXPERIMENTAL MONKEY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; LEUKOCYTE COUNT; MALE; MONOCYTE; NONHUMAN; ORGAN WEIGHT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; SPLEEN WEIGHT; T LYMPHOCYTE; ANIMAL; ANTIBODY PRODUCTION; CELL MOTION; CELL PROLIFERATION; CELL STRAIN K 562; CLINICAL TRIAL; CROHN DISEASE; CYTOTOXICITY; HEMATOPOIESIS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MACACA; METABOLISM; MULTIPLE SCLEROSIS; ORGAN SIZE; PATHOLOGY; SECRETION; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

MACACA FASCICULARIS; MACACA MULATTA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD; B-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HEMATOPOIESIS; HUMANS; IMMUNOTHERAPY; INTEGRIN ALPHA4; K562 CELLS; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MACACA MULATTA; MULTIPLE SCLEROSIS; ORGAN SIZE; STEM CELLS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 65549122864     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910902977381     Document Type: Article

References (32)

1. Arroyo, A. G., Yang, J. T., Rayburn, H., and Hynes, R. O. 1996. Differential requirements for d¢4 integrins during fetal and adult hematopoiesis. Cell 85:997-1008.
2. Arroyo, A. G., Yang, J. T., Rayburn, H., and Hynes, R. O. 1999. d¢4 integrins regulate the proliferation/differentiation balance of multi-lineage hematopoietic progenitors in vivo. Immunity. 11:555-566.
3. Banerjee, E. R., Latchman, Y. E., Jiang, Y., Priestley, G. V., and Papayannopoulou, T. 2008. Distinct changes in adult lymphopoiesis in Rag2-/- mice fully reconstituted by d¢4-deficient adult bone marrow cells. Exp. Hematol. 36:1004-1013.
4. Christensen, B. E., Jønsson, V., Matre, R., and Tønder, O. 1978. Traffic of T- and B-lymphocytes in the normal spleen. Scand. J. Haematol. 20:246-257.
5. Danese, S., Semeraro, S., Marini, M., Roberto, I., Armuzzi, A., Papa, A., and Gasbarrini, A. 2005. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig. Liver. Dis. 37:811-818.
6. Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., and Donoghue, S. 2003. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348:24-32.
7. Gordon, F. H., Lai, C. W., Hamilton, M. I., Allison, M. C., Srivastava, E. D., Fouweather, M. G., Donoghue, S., Greenlees, C., Subhani, J., Amlot, P. L., and Pounder, R. E. 2001. A randomized placebo-controlled trial of a humanized monoclonal antibody to d¢4 integrin in active Crohn's disease. Gastroenterology 121:268-274.
8. Heilbronn, R., Albrecht, I., Stephan, S., Bürkle, A., and zur Hausen, H. 1993. Human cytomegalovirus induces JC virus DNA replication in human fibroblasts. Proc. Natl. Acad. Sci. USA 90:11406-11410.
9. Hyams, J. S., Wilson, D. C., Thomas, A., Heuschkel, R., Mitton, S., Mitchell, B., Daniels, R., Libonati, M. A., Zanker, S., and Kugathasan, S. 2007. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44:185-191.
10. Kleinschmidt-DeMasters, B.K., and Tyler, K.L. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon d£-1a for multiple sclerosis. N. Engl. J. Med. 353:369-374.
11. Knowles, D. M., Cesarman, E., Chadburn, A., Frizzera, G., Chen, J., Rose, E. A., and Michler, R. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post-transplantation lymphoproliferative disorders. Blood 85:552-565.
12. Langer-Gould, A., Atlas, S.W., Green, A.J., Bollen, A.W., and Pelletier, D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375-381.
13. Lasky, L. A. 1996. Hematopoiesis: Wandering progenitor cells. Curr. Biol. 6:1238-1240.
14. Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., Loewen, G. M., Creaven, P. J., Wilkes, K. A., Giedlin, M. A., and Caligiuri, M. A. 1996. Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity. Clin. Cancer. Res. 2:669-677.
15. Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., and O'Connor, P. W. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15-23.
16. Mirandola, P., Ponti, C., Gobbi, G., Sponzilli, I., Melloni, E., and Vitale, M. 2004. The response of human natural killer cells to interleukin-2. J. Endocrinol. Invest. 27 (S6):146-150.
17. Naume, B., and Espevik, T. 1991. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J. Immunol. 147:2208-2214.
18. National Center for Biotechnology Information (NCBI). Gen Bank accession number XM 001100929. http://www.ncbi.nlm.nih.gov. Accessed 26 March 2009.
19. Oostendorp R. A., and Dörmer, P. 1997. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Leuk. Lymphoma 24:423-435.
20. Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899-910. (Pubitemid 43313657)
21. Qian, H., Georges-Labouesse, E., Nyström, A., Domogatskaya, A., Tryggvason, K., Jacobsen, S. E., and Ekblom, M. 2007. Distinct roles of integrins d¢6 and d¢4 in homing of fetal liver hematopoietic stem and progenitor cells. Blood 110:2399-2407.
22. Robinson, B. W., and Morstyn, G. 1987. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells. Cell. Immunol. 106:215-222.
23. Rose, D. M., Han, J., and Ginsberg, M. H. 2002. d¢4 integrins and the immune response. Immunol. Rev. 186:118-124.
24. Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. Natalizumab plus interferon d£-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354:911-923. (Pubitemid 43313658)
25. Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., van Deventer, S., Goldblum, R., Despain, D., Hogge, G. S., and Rutgeerts, P. 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353:1912-1925. (Pubitemid 41565956)
26. Sands, B. E., Kozarek, R., Spainhour, J., Barish, C. F., Becker, S., Goldberg, L., Katz, S., Goldblum, R., Harrigan, R., Hilton, D., and Hanauer, S. B. 2007. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm. Bowel. Dis. 13:2-11.
27. Schmidtko, J., Wang, R., Wu, C., Mauiyyedi, S., Harris, N., Della Pelle, P., Brousaides, N., Zagachin, L., Ferry, J., Wang, F., Kawai, T., Sachs, D., Cosimi, B.,and Colvin, R. 2002. Post-transplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 73:1431-1439.
28. Stüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., Cook, L., Grand'Maison, F., Hemmer, B., Monson, N. L., and Racke, M. K. 2006. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63:1383-1387.
29. TYSABRI.2008. [Package insert]. Elan Pharmaceuticals, Inc. South San Francisco, CA; http://www.tysabri.com.
30. Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., and Rutgeerts, P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353:362-368.
31. Willführ, K. U., Westermann, J., and Pabst, R. 1990. Absolute numbers of lymphocytes subsets migrating through the compartments of the normal and transplanted rat spleen. Eur. J. Immunol . 20:903-911.
32. Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E. W., Jäger, H. R., and Clifford, D. B. 2006. Evaluation patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354:924-933.